Parallel Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.72M | Buy |
8,718
+1,056
| +14% | +$204K | 0.03% | 332 |
|
|
2025
Q4 | $1.41M | Buy |
7,662
+227
| +3% | +$39.8K | 0.03% | 360 |
|
|
2025
Q3 | $1.14M | Buy |
7,435
+465
| +7% | +$70.4K | 0.02% | 392 |
|
|
2025
Q2 | $974K | Sell |
6,970
-1,055
| -13% | -$148K | 0.02% | 425 |
|
|
2025
Q1 | $1.18M | Buy |
8,025
+563
| +8% | +$81.5K | 0.03% | 360 |
|
|
2024
Q4 | $978K | Sell |
7,462
-3,036
| -29% | -$425K | 0.02% | 408 |
|
|
2024
Q3 | $1.64M | Buy |
10,498
+121
| +1% | +$19.5K | 0.04% | 281 |
|
|
2024
Q2 | $1.62M | Buy |
10,377
+992
| +11% | +$149K | 0.04% | 266 |
|
|
2024
Q1 | $1.27M | Buy |
9,385
+2,229
| +31% | +$295K | 0.03% | 310 |
|
|
2023
Q4 | $964K | Sell |
7,156
-85
| -1% | -$11.1K | 0.03% | 338 |
|
|
2023
Q3 | $981K | Buy |
7,241
+325
| +5% | +$44.4K | 0.03% | 316 |
|
|
2023
Q2 | $990K | Buy |
6,916
+214
| +3% | +$31.5K | 0.03% | 316 |
|
|
2023
Q1 | $930K | Buy |
6,702
+89
| +1% | +$12K | 0.03% | 326 |
|
|
2022
Q4 | $897K | Sell |
6,613
-412
| -6% | -$51.7K | 0.04% | 278 |
|
|
2022
Q3 | $770K | Buy |
7,025
+1,300
| +23% | +$165K | 0.04% | 288 |
|
|
2022
Q2 | $757K | Sell |
5,725
-114
| -2% | -$15K | 0.03% | 289 |
|
|
2022
Q1 | $784K | Sell |
5,839
-1,251
| -18% | -$150K | 0.03% | 318 |
|
|
2021
Q4 | $826K | Buy |
7,090
+111
| +2% | +$13.1K | 0.03% | 317 |
|
|
2021
Q3 | $838K | Buy |
6,979
+1,134
| +19% | +$132K | 0.03% | 290 |
|
|
2021
Q2 | $700K | Buy |
5,845
+328
| +6% | +$36K | 0.03% | 319 |
|
|
2021
Q1 | $549K | Sell |
5,517
-312
| -5% | -$31.4K | 0.03% | 329 |
|
|
2020
Q4 | $583K | Sell |
5,829
-155
| -3% | -$16.4K | 0.03% | 301 |
|
|
2020
Q3 | $656K | Buy |
5,984
+93
| +2% | +$10.3K | 0.04% | 250 |
|
|
2020
Q2 | $623K | Sell |
5,891
-126
| -2% | -$13K | 0.04% | 257 |
|
|
2020
Q1 | $537K | Buy |
6,017
+424
| +8% | +$39.9K | 0.04% | 230 |
|
|
2019
Q4 | $558K | Sell |
5,593
-225
| -4% | -$21.2K | 0.04% | 265 |
|
|
2019
Q3 | $519K | Buy |
5,818
+562
| +11% | +$48.7K | 0.04% | 258 |
|
|
2019
Q2 | $434K | Sell |
5,256
-540
| -9% | -$42.3K | 0.04% | 267 |
|
|
2019
Q1 | $469K | Buy |
5,796
+250
| +5% | +$19.7K | 0.05% | 231 |
|
|
2018
Q4 | $421K | Buy |
5,546
+438
| +9% | +$34.2K | 0.06% | 218 |
|
|
2018
Q3 | $404K | Sell |
5,108
-25
| -0.5% | -$1.89K | 0.05% | 242 |
|
|
2018
Q2 | $360K | Buy |
5,133
+18
| +0.4% | +$1.29K | 0.05% | 229 |
|
|
2018
Q1 | $358K | Buy |
5,115
+483
| +10% | +$33.5K | 0.06% | 227 |
|
|
2017
Q4 | $321K | Sell |
4,632
-129
| -3% | -$8.7K | 0.05% | 241 |
|
|
2017
Q3 | $313K | Buy |
4,761
+1,268
| +36% | +$80.1K | 0.05% | 241 |
|
|
2017
Q2 | $211K | Buy |
3,493
+1,230
| +54% | +$80.3K | 0.04% | 307 |
|
|
2017
Q1 | $138K | Buy |
2,263
+482
| +27% | +$28.1K | 0.03% | 367 |
|
|
2016
Q4 | $97K | Buy |
+1,781
| New | +$101K | 0.02% | 395 |
|
Other funds holding AZN
IA
VCM
VAM
Parallel Advisors's AZN Position: Q1 2026 in Review
Parallel Advisors increased its AstraZeneca (AZN) stake by 14% in Q1 2026, buying an estimated $204K and bringing the position to 8,718 shares worth $1.72M. The position accounts for 0.03% of the portfolio, ranked #332.
Parallel Advisors first reported a position in AZN in Q4 2016 and has held it in 38 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Parallel Advisors held 8,718 shares of AstraZeneca worth $1.72M as of Q1 2026.
- Parallel Advisors bought 1,056 AstraZeneca shares in Q1 2026, an estimated $204K.
- AstraZeneca made up 0.03% of Parallel Advisors's portfolio in Q1 2026, its #332 holding.
- Parallel Advisors first reported a position in AstraZeneca in Q4 2016 and has held it in 38 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.